Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors

NCT04090034

Status	RECRUITING
Sponsor	Methodist Health System
Enrollment	50 participants

Key Eligibility Criteria

Inclusion (16)

- \> 18 years of age
- Diagnosed with gastroenteropancreatic primary NET and has consented to undergo PRRT per the treating physician. Specifically:
- Will consider other primaries on a case by case basis if dotatate scan (+) and meet all other criteria.
- Metastatic or Locally Advanced AND Inoperable
- Clear disease progression on Octreotide over less than 3 years (RECIST 1.1)

... and 11 more (see full listing online)

Locations (2 total)

Clinical Research Institute at Methodist Health System, Dallas, Texas, United States
Methodist Dallas Medical Center, Dallas, Texas, United States

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.